CriticalFirst-generation antihistamine with anxiolytic activity×Class Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)
Updated · Methodology
Mechanism
Hydroxyzine is associated with QT prolongation. Post-marketing cases of QT prolongation and torsade de pointes occurred mostly in people with other risk factors, electrolyte disturbances or concomitant medicines (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Like other class IA antiarrhythmics, quinidine prolongs the QTc interval, which can lead to torsade de pointes, a life-threatening ventricular arrhythmia (quinidine label, US Food and Drug Administration, FDA). The Spanish hydroxyzine SmPC names quinidine among the drugs that raise the risk of arrhythmia when taken with hydroxyzine (AEMPS). Quinidine also has anticholinergic actions that may add to those of other drugs with these effects (quinidine FDA label). The Spanish hydroxyzine SmPC says to adjust the hydroxyzine dose for each patient when combining it with anticholinergic drugs (AEMPS). CYP3A4 is the main enzyme that metabolises quinidine. Hydroxyzine inhibits this enzyme only at concentrations above peak plasma levels and is unlikely to change the metabolism of its substrates (quinidine FDA label; hydroxyzine SmPC, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Besides torsade de pointes, quinidine can cause frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation. The risk of torsade de pointes rises with a slow heart rate, low potassium, magnesium or calcium and high quinidine levels, but it can occur without these factors (quinidine label, US Food and Drug Administration, FDA). The adverse reactions of hydroxyzine include QT prolongation, ventricular arrhythmias and loss of consciousness (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Because of its anticholinergic effect, hydroxyzine can cause dry mouth, urinary retention, constipation and blurred vision. Its SmPC advises caution in glaucoma, bladder outflow obstruction, reduced gut motility, myasthenia gravis and dementia (hydroxyzine SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish hydroxyzine summary of product characteristics (SmPC) contraindicates hydroxyzine with drugs that prolong the QT interval or cause torsade de pointes and names quinidine (hydroxyzine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US hydroxyzine label only advises caution with quinidine, and the US quinidine label does not name hydroxyzine (hydroxyzine and quinidine labels, US Food and Drug Administration, FDA); the Spanish hydroxyzine SmPC is stricter. Hydroxyzine is also contraindicated in known QT prolongation, cardiovascular disease, low potassium or magnesium, a family history of sudden cardiac death and significant bradycardia (hydroxyzine SmPC, AEMPS). Use quinidine with extreme care in pre-existing long QT syndrome, a history of torsade de pointes of any cause, or previous marked QTc lengthening in response to quinidine or other drugs that prolong ventricular repolarisation (quinidine FDA label). Quinidine is contraindicated in people for whom an anticholinergic effect could be harmful, such as those with myasthenia gravis (quinidine FDA label). Adjust the hydroxyzine dose for each patient when combining it with anticholinergic drugs (hydroxyzine SmPC, AEMPS). If hydroxyzine and quinidine have nevertheless been taken together and signs of arrhythmia appear, stop hydroxyzine (hydroxyzine SmPC, AEMPS). In haemodynamically unstable polymorphic ventricular tachycardia, including torsade de pointes, stop quinidine and perform immediate cardioversion or overdrive pacing. Look for low potassium, magnesium and calcium and, if possible, correct them promptly (quinidine FDA label, overdosage section).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Quinidine Sulfate Tablets USP (quinidine sulfate) prescribing information (2023)– FDA, DailyMed setid b0d6341b-d880-4f0b-8844-bc788c03004a (Epic Pharma), revisión 11/2023, secciones Clinical Pharmacology, Warnings, Precautions (Drug Interactions) y Overdosage
- AEMPS: Ficha técnica: Hidroxizina (nº registro 26308), sección 4.5 (2023)– AEMPS, CIMA, nº registro 26308 (Atarax 25 mg comprimidos recubiertos con película, UCB Pharma), revisión 02/2023, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: Hydroxyzine Hydrochloride Tablets, USP (hydroxyzine) prescribing information (2026)– FDA, DailyMed setid 9de2de56-614f-4294-8794-d30758cf5f70 (Aurobindo Pharma), revisión 03/2026 (versión 2), Contraindications, Precautions (QT Prolongation/Torsade de Pointes), Overdosage